Status of RASSF1A in uveal melanocytes and melanoma cells

Molecular Cancer Research

Volumn 9, Issue 9, 2011, Pages 1187-1198

  Calipel, Armelle ^a,b   Abonnet, Véronique ^a   Nicole, Olivier ^b   Mascarelli, Frédéric ^c,d   Coupland, Sarah E ^e   Damato, Bertil ^e   Mouriaux, Frédéric ^a,b  

^a CAEN UNIVERSITY HOSPITAL   (France)

^b UNIVERSITÉ DE CAEN   (France)

^c CENTRE DE RECHERCHE DES CORDELIERS   (France)

^d UNIVERSITÉ PARIS DESCARTES   (France)

^e ROYAL LIVERPOOL UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BETA GALACTOSIDASE; CYCLIN D1; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PROTEIN P21; PROTEIN P27; RAS ASSOCIATION DOMAIN FAMILY PROTEIN 1A; SMALL INTERFERING RNA;

ANCHORAGE INDEPENDENT GROWTH; ARTICLE; CANCER CELL CULTURE; CELL LINE; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVITY; HUMAN; HUMAN CELL; HUMAN TISSUE; MELANOCYTE; MELANOMA CELL; METHYLATION; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN FUNCTION; UVEA MELANOMA;

CELL AGING; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLIN D1; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLIN-DEPENDENT KINASE INHIBITOR P27; DNA METHYLATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LOSS OF HETEROZYGOSITY; MAP KINASE SIGNALING SYSTEM; MELANOCYTES; MELANOMA; PROMOTER REGIONS, GENETIC; RNA, SMALL INTERFERING; TUMOR SUPPRESSOR PROTEINS; UVEAL NEOPLASMS;

EID: 80052845051     PISSN: 15417786     EISSN: 15573125     Source Type: Journal    
DOI: 10.1158/1541-7786.MCR-10-0437     Document Type: Article

References (40)

1. van der Weyden L, Adams DJ. The Ras-association domain family (RASSF) members and their role in human tumourigenesis. Biochim Biophys Acta 2007;1776:58-85. (Pubitemid 47332074)
2. Vos MD, Clark GJ. RASSF family proteins and ras transformation. Methods Enzymol 2006;407:311-22.
3. Agathanggelou A, Cooper WN, Latif F. Role of the ras-association domain family 1 tumor suppressor gene in human cancers. Cancer Res 2005;65:3497-508. (Pubitemid 40616319)
4. Dammann R, Li C, Yoon JH, Chin PL, Bates S, Pfeifer GP. Epigenetic inactivation of a ras association domain family protein from the lung tumour suppressor locus 3p21.3. Nat Genet 2000;25:315-9. (Pubitemid 30437320)
5. Spugnardi M, Tommasi S, Dammann R, Pfeifer GP, Hoon DSB. Epigenetic inactivation of RAS association domain family protein 1 (RASSF1A) in malignant cutaneous melanoma. Cancer Res 2003;63:1639-43. (Pubitemid 36373656)
6. Liu L, Guo C, Dammann R, Tommasi S, Pfeifer GP. RASSF1A interacts with and activates the mitotic kinase aurora-A. Oncogene 2008;27:6175-86.
7. Kuzmin I, Gillespie JW, Protopopov A, Geil L, Dreijerink K, Yang Y, et al. The RASSF1A tumor suppressor gene is inactivated in prostate tumors and suppresses growth of prostate carcinoma cells. Cancer Res 2002;62:3498-502. (Pubitemid 34651398)
8. Dreijerink K, Braga E, Kuzmin I, Geil L, Duh FM, Angeloni D, et al. The candidate tumor suppressor gene, RASSF1A, from human chromosome 3p21.3 is involved in kidney tumorigenesis. Proc Natl Acad Sci U S A 2001;98:7504-9. (Pubitemid 32567978)
9. Tommasi S, Dammann R, Zhang Z, Wang Y, Liu L, Tsark WM, et al. Tumor susceptibility of rassf1a knockout mice. Cancer Res 2005;65:92-8. (Pubitemid 40070799)
10. Reifenberger J, Knobbe CB, Sterzinger AA, Blaschke B, Schulte KW, Ruzicka T, et al. Frequent alterations of ras signaling pathway genes in sporadic malignant melanomas. Int J Cancer 2004;109:377-84. (Pubitemid 38252766)
11. Tschentscher F, Prescher G, Horsman DE, White VA, Rieder H, Anastassiou G, et al. Partial deletions of the long and short arm of chromosome 3 point to two tumor suppressor genes in uveal melanoma. Cancer Res 2001;61:3439-42. (Pubitemid 32695038)
12. Damato B, Dopierala J, Klaasen A, van Dijk M, Sibbring J, Coupland SE. Multiplex ligation-dependent probe amplification of uveal melanoma: correlation with metastatic death. Invest Ophthalmol Vis Sci 2009;50:3048-55.
13. Rimoldi D, Salvi S, Liénard D, Lejeune FJ, Speiser D, Zografos L, et al. Lack of braf mutations in uveal melanoma. Cancer Res 2003;63:5712-5. (Pubitemid 37187465)
14. Malaponte G, Libra M, Gangemi P, Bevelacqua V, Mangano K, D'Amico F, et al. Detection of braf gene mutation in primary choroidal melanoma tissue. Cancer Biol Ther 2006;5:225-7. (Pubitemid 43327543)
15. Gear H, Williams H, Kemp EG, Roberts F. Braf mutations in conjunctival melanoma. Invest Ophthalmol Vis Sci 2004;45:2484-8. (Pubitemid 38998840)
16. Calipel A, Mouriaux F, Glotin A, Malecaze F, Faussat A, Mascarelli F. Extracellular signal-regulated kinase-dependent proliferation is mediated through the protein kinase A/B-Raf pathway in human uveal melanoma cells. J Biol Chem 2006;281:9238-50. (Pubitemid 43864639)
17. Van Raamsdonk CD, Bezrookove V, Green G, Bauer J, Gaugler L, O'Brien JM, et al. Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi. Nature 2009;457:599-602.
18. Van Raamsdonk CD, Griewank KG, Crosby MB, Garrido MC, Vemula S, Wiesner T, et al. Mutations in GNA11 in uveal melanoma. N Engl J Med 2010;363:2191-9.
19. Merhavi E, Cohen Y, Avraham BCR, Frenkel S, Chowers I, Pe'er J, et al. Promoter methylation status of multiple genes in uveal melanoma. Invest Ophthalmol Vis Sci 2007;48:4403-6.
20. Maat W, van der Velden PA, Out-Luiting C, Plug M, Dirks-Mulder A, Jager MJ, et al. Epigenetic inactivation of RASSF1a in uveal melanoma. Invest Ophthalmol Vis Sci 2007;48:486-90. (Pubitemid 351260675)
21. Fridman AL, Tainsky MA. Critical pathways in cellular senescence and immortalization revealed by gene expression profiling. Oncogene 2008;27:5975-87.
22. Michaloglou C, Vredeveld LCW, Soengas MS, Denoyelle C, Kuilman T, van der Horst CMAM, et al. Brafe600-associated senescence-like cell cycle arrest of human naevi. Nature 2005;436:720-4. (Pubitemid 41117276)
23. Lin AW, Barradas M, Stone JC, van Aelst L, Serrano M, Lowe SW. Premature senescence involving p53 and p16 is activated in response to constitutive MEK/MAPK mitogenic signaling. Genes Dev 1998;12:3008-19. (Pubitemid 28469303)
24. Mooi WJ, Peeper DS. Oncogene-induced cell senescence-halting on the road to cancer. N Engl J Med 2006;355:1037-46. (Pubitemid 44343547)
25. Grønbaek K, Treppendahl M, Asmar F, Guldberg P. Epigenetic changes in cancer as potential targets for prophylaxis and maintenance therapy. Basic Clin Pharmacol Toxicol 2008;103:389-96.
26. Mouriaux F, Casagrande F, Pillaire MJ, Manenti S, Malecaze F, Darbon JM. Differential expression of g1 cyclins and cyclin-dependent kinase inhibitors in normal and transformed melanocytes. Invest Ophthalmol Vis Sci 1998;39:876-84. (Pubitemid 28196673)
27. Folberg R, Kadkol SS, Frenkel S, Valyi-Nagy K, Jager MJ, Pe'er J, et al. Authenticating cell lines in ophthalmic research laboratories. Invest Ophthalmol Vis Sci 2008;49:4697-701.
28. Vos MD, Ellis CA, Bell A, Birrer MJ, Clark GJ. Ras uses the novel tumor suppressor RASSF1 as an effector to mediate apoptosis. J Biol Chem 2000;275:35669-72.
29. Ahmed-Choudhury J, Agathanggelou A, Fenton SL, Ricketts C, Clark GJ, Maher ER, et al. Transcriptional regulation of cyclin A2 by RASSF1A through the enhanced binding of p120E4F to the cyclin A2 promoter. Cancer Res 2005;65:2690-7. (Pubitemid 40490069)
30. Calipel A, Lefevre G, Pouponnot C, Mouriaux F, Eychène A, Mascarelli F. Mutation of B-Raf in human choroidal melanoma cells mediates cell proliferation and transformation through the MEK/ERK pathway. J Biol Chem 2003;278:42409-18. (Pubitemid 37310512)
31. Lefèvre G, Babchia N, Calipel A, Mouriaux F, Faussat A, Mrzyk S, et al. Activation of the FGF2/FGFR1 autocrine loop for cell proliferation and survival in uveal melanoma cells. Invest Ophthalmol Vis Sci 2009;50:1047-57.
32. Hu DN, McCormick SA, Ritch R. Studies of human uveal melanocytes in vitro: growth regulation of cultured human uveal melanocytes. Invest Ophthalmol Vis Sci 1993;34:2220-7. (Pubitemid 23191248)
33. Lefevre G, Calipel A, Mouriaux F, Hecquet C, Malecaze F, Mascarelli F. Opposite long-term regulation of c-Myc and p27Kip1 through overactivation of Raf-1 and the MEK/ERK module in proliferating human choroidal melanoma cells. Oncogene 2003;22:8813-22. (Pubitemid 38021497)
34. Dimri GP, Lee X, Basile G, Acosta M, Scott G, Roskelley C, et al. A biomarker that identifies senescent human cells in culture and in aging skin in vivo. Proc Natl Acad Sci U S A 1995;92:9363-7.
35. Onken MD, Worley LA, Long MD, Duan S, Council ML, Bowcock AM, et al. Oncogenic mutations in GNAQ occur early in uveal melanoma. Invest Ophthalmol Vis Sci 2008;49:5230-4.
36. Shivakumar L, Minna J, Sakamaki T, Pestell R, White MA. The RASSF1A tumor suppressor blocks cell cycle progression and inhibits cyclin D1 accumulation. Mol Cell Biol 2002;22:4309-18. (Pubitemid 34556598)
37. Whang YM, Kim YH, Kim JS, Yoo YD. RASSF1A suppresses the c-Jun-NH2-kinase pathway and inhibits cell cycle progression. Cancer Res 2005;65:3682-90. (Pubitemid 40616345)
38. Coupland SE, Bechrakis N, Schüler A, Anagnostopoulos I, Hummel M, Bornfeld N, et al. Expression patterns of cyclin D1 and related proteins regulating G1-S phase transition in uveal melanoma and retinoblastoma. Br J Ophthalmol 1998;82:961-70. (Pubitemid 28408159)
39. Mouriaux F, Maurage CA, Labalette P, Sablonnière B, Malecaze F, Darbon JM. Cyclin-dependent kinase inhibitory protein expression in human choroidal melanoma tumors. Invest Ophthalmol Vis Sci 2000;41:2837-43.
40. Boucher M, Jean D, Vézina A, Rivard N. Dual role of MEK/ERK signaling in senescence and transformation of intestinal epithelial cells. Am J Physiol Gastrointest Liver Physiol 2004;286:G736-46.